問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳彥豪
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

142Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳彥豪

List

264Cases

2026-01-27 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

  • Condition/Disease

    Oesophageal Squamous Cell Carcinoma

  • Test Drug

    ifinatamab deruxtecan (I-DXd)

Participate Sites
7Sites

Recruiting7Sites

2023-09-01 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2023-09-01 - 2027-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-09-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-11-15 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting1Sites

2023-12-01 - 2026-11-01

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2023-12-01 - 2031-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2023-12-01 - 2027-03-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

2025-10-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

  • Condition/Disease

    Gastrointestinal Neoplasms

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB